Africa — While the world focuses on wars, elections, and economic upheaval, a quieter catastrophe is unfolding across the African continent — one that already claims more lives than HIV/AIDS, tuberculosis, and malaria combined. Antimicrobial resistance (AMR), the process by which bacteria, viruses, fungi, and parasites evolve to defeat the drugs designed to kill them, has taken root in Africa with devastating speed.
New data presented at a recent “One Health” summit in France paints a grim picture: Africa is bearing the brunt of a global AMR crisis that health experts warn could render modern medicine ineffective within a generation.
The Scale of the Crisis
In high-income countries, AMR-related mortality is estimated at approximately 13 deaths per 100,000 people. In Africa, that figure doubles to 27.3 deaths per 100,000 — exceeding the combined mortality burden of the three diseases that traditionally dominate global health headlines. The reason is straightforward: Africa has the highest infectious disease burden in the world, which drives massive antibiotic consumption — much of it unnecessary, unregulated, and ineffective.
Antibiotics are dispensed without prescriptions in the vast majority of African pharmacies. A patient with a fever walks in, receives a course of amoxicillin or ciprofloxacin, and recovers — whether the drug had any effect or not. The pathogens that survive go on to reproduce, mutating toward resistance.
A Perfect Storm
Africa’s AMR crisis is driven by a convergence of factors unique to the continent:
- Weak regulatory frameworks: Most African countries lack robust systems for monitoring antibiotic prescription and use. In many places, the same drugs that require a prescription in Europe are sold over the counter with no questions asked.
- Overcrowded hospitals and poor infection control: Healthcare facilities in much of sub-Saharan Africa lack running water, adequate sanitation, and isolation capacity.
- Agricultural use of antibiotics: Livestock farming increasingly relies on antibiotics as growth promoters and preventive medicine — a practice that directly accelerates resistance evolution.
- Limited diagnostic capacity: A patient with a viral infection may receive antibiotics because the diagnostic tools to confirm the cause of illness are unavailable.
The Human Consequences
The consequences of AMR are not abstract. They are measured in failed surgeries, untreatable pneumonia, resistant bloodstream infections, and mothers who die from routine cesarean sections that become fatal when antibiotic prophylaxis fails.
In Kenya, Uganda, Tanzania, and Nigeria, hospitals have reported a dramatic rise in resistant strains of Klebsiella pneumoniae. In South Africa, the emergence of extensively drug-resistant tuberculosis (XDR-TB) has forced doctors to use experimental regimens with severe side effects.
What Can Be Done?
The solutions are known — they are a matter of political will and resources. Surveillance networks, public awareness campaigns, regulatory enforcement on over-the-counter antibiotic sales, and limits on agricultural antibiotic use are all achievable with the right investment.
Africa needs a continent-wide AMR surveillance system, comparable to the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). Several countries have begun implementing lab-based surveillance, but coverage remains patchy.
A Race Against Time
Antimicrobial resistance does not make headlines the way wars or pandemics do. There are no dramatic evacuation flights, no celebrity telethons, no emergency summits with world leaders pledging billions. But the death toll from AMR in Africa is already comparable to — and will soon exceed — some of the world’s most feared diseases.
The “One Health” framework — recognizing the interconnection of human, animal, and environmental health — is the right approach. But frameworks are not treatments. What Africa needs now is investment, enforcement, and urgency commensurate with a crisis that is already here.
Sources: France 24, KEMRI, Gavi Vaccines Work, Nature (March 2026)